Browsing Tag
San Diego
60 posts
Nayax shares jump 13% on $350 million IPS Group deal as smart parking opportunity expands
Nayax is buying IPS Group for $350M, adding $90M of smart-parking revenue and expanding its cashless market opportunity by $85B.
ResMed’s FY27 guidance reset tests investor confidence in sleep-apnea device growth
ResMed’s FY27 guidance reset pressured RMD despite strong cash flow. Read how Astral, GLP-1 drugs, MatrixCare and buybacks shape the medtech story.
ResMed (ASX: RMD) drops 8% as Astral recall clouds FY27 outlook
ResMed fell 8% as FY27 sales guidance missed expectations. Astral recall costs and slower growth now test the ASX: RMD valuation.
Why Capstone Energy+’s Scripps Mercy project matters more than its 2 MW capacity suggests
The Scripps Mercy Hospital installation gives Capstone Energy+ a high-value healthcare reference, but commissioning, verified economics and repeat orders will determine its commercial significance.
Everest Medicines closes $1.14bn Travere deal for rare kidney disease drug
Everest Medicines closes its $1.14 billion Travere deal for civorebrutinib. Read how the BTK licence reshapes 1952.HK, TVTX and rare kidney strategy.
Why ABB’s NASCAR microgrid showcase could matter beyond motorsports
Find out how ABB’s NASCAR Grid Control could shape ABBN stock sentiment, microgrid demand and temporary event power strategy today!
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.
Avacta FY25 puts AVCT on a clock: £16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, £16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.
San Diego mosque shooting: Three men killed, two teenage suspects found dead
A mosque, a school and a hate-crime probe now converge in San Diego. The Islamic Center attack renews scrutiny of religious-site security.
PCI Pharma Services bets over $1bn on US sterile fill-finish capacity as drug supply chains localize
Drugmakers want US capacity, but sterile fill-finish remains scarce. PCI Pharma Services is betting over $1B that resilience now wins contracts.